CTNI-70. LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY

PURPOSE: Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Rulseh, Aaron, Derner, Adam, Sroubek, Jan, Klener, Jan, Vymazal, Josef
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Clinical Trials: Non-Immunologic
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651202/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.236
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller